Briefs: Horizon secures £0.1m funding: DisplayLink opens office in Seattle
Targeted drug discovery company Horizon Discovery Ltd has received further investment of £100,000 from Cambridge Enterprise Seed Funds. The cash injection will support activity to close further significant third party deals, establish wet lab facilities and consolidate the company’s IP portfolio.
Founded in June 2007, Horizon Discovery uses a novel gene-engineering technology to create genetically-defined human disease models called ‘isogenic’ cell-lines. These human isogenic cell-lines provide the first accurate laboratory based models of human genetic diseases and their matched normal cell-types. Isogenic cell-lines will therefore speed-up and reduce the cost of discovering novel ‘personalised’ drugs that target the fundamental causes of diseases such as cancer.
Horizon Discovery has already demonstrated its commercial potential with notable agreements and licences to large pharmaceutical and biotechnology companies over the past nine months. The company has just agreed a co-marketing and distribution relationship with a multi-national Life Science company, a fact that will see its products and services reach a global audience.
Cambridge Enterprise Seed Funds first supported Horizon Discovery with a convertible loan in July 2007. Dr Geraldine Rodgers, Head of Seed Funds, said “Horizon Discovery has achieved a great amount to date. We have high hopes for the success and profitability of Horizon Discovery in the future.”
# # # #
DisplayLink has opened a new office in Seattle. The office will serve as a base for network display software development, while supporting projects with area partners such as Microsoft and Intel.
DisplayLink said it offers unique opportunities for Seattle software engineers. Unlike the region’s many Web 2.0 startups, DisplayLink is a venture-financed, pre-IPO startup that sells both chips and software. Its technology is already widely available in products from Samsung, Toshiba, LG, Kensington, Belkin, and many other leading brands.
# # # #
Data quality specialists Datanomic Ltd, said that BT Global Services, has adopted its dn:Director enterprise data quality management application to cleanse, de-duplicate, validate and structure patient data for maximum efficiency in the implementation of its major data migration project. dn:Director will audit the accuracy and completeness of patient data records, spanning up to two decades, involving hundreds of thousands of detailed patient records.
BT Global Services is a key supplier to the healthcare industry, providing technology and services. BT is committed to helping its clients exploit the right technology and make services more accessible, efficient and effective.
# # # #
Meridio, an Autonomy company and the leading provider of Records Management software, said the UK Government's Cabinet Office has deployed its records management solution to manage and control hundreds of thousands of electronic documents and records across the government organization.
8 April 2008
